Majority of Patients Require Few Opioids After Hernia Repair

This article originally appeared here.
Share this content:
Majority of Patients Require Few Opioids After Hernia Repair
Majority of Patients Require Few Opioids After Hernia Repair

TUESDAY, Aug. 15, 2017 (HealthDay News) -- The number of opioids prescribed for patients after elective hernia repair can be reduced, according to a study published online Aug. 1 in Surgery.

Konstantinos S. Mylonas, M.D., from Massachusetts General Hospital in Boston, and colleagues surveyed 185 adult patients (95.7 percent male) undergoing elective inguinal herniorrhaphy under local anesthesia with intravenous sedation between Oct. 1, 2015, and Sept. 30, 2016. The surveys were conducted two to three weeks postoperatively and included questions about the institution's opioid prescribing practice. Patients were prescribed 10 opioid analgesic tablets postoperatively but were counseled to reserve opioids for pain not controlled by nonopioid analgesics.

The researchers found that 85.9 percent of patients reported using four or fewer opioid tablets, with 59.5 percent reporting that they used no opioid analgesics postoperatively. Of the 147 employed patients, 75.5 percent reported missing three or fewer work days, with 51.4 percent missing no work at all. Patients who used no opioids reported experiencing less maximum (P < 0.001) and persistent groin pain (P = 0.037). They also reported that pain interfered less with daily activities (P = 0.012) and leisure activities (P = 0.018), compared to patients who did take opioids.

"Our data suggest that for elective inguinal hernia repair under a local anesthetic with intravenous sedation, a policy of low opioid analgesic prescribing is achievable," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »